A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Ladiratuzumab-Vedotin (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seattle Genetics
- 26 Aug 2019 Planned number of patients changed from 366 to 378.
- 26 Aug 2019 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
- 26 Aug 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Nov 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History